10-Q: Calidi Biotherapeutics Reports Q2 2026 Results, Faces Going Concern Doubt

Calidi Biotherapeutics, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing operational losses and significant accumulated deficit, leading to substantial doubt about its ability to continue as a going concern.

Summary

• Calidi Biotherapeutics, Inc. reported its financial results for the quarter and six months ended June 30, 2026.
• The company experienced net losses of $4.16 million for the three months and $8.27 million for the six months ended June 30, 2026.
• As of June 30, 2026, the company had an accumulated deficit of $149.9 million.
• There is substantial doubt about the company's ability to continue as a going concern within 12 months from the issuance date of the financial statements.
• The company plans to raise additional capital through equity or debt financings to meet its operating and capital requirements.
• A 1-for-16 reverse stock split was effected on July 30, 2026, with trading commencing on a split-adjusted basis on July 31, 2026.
• Research and development expenses were relatively flat year-over-year for the three-month period but increased slightly for the six-month period.
• General and administrative expenses decreased significantly in both the three-month and six-month periods compared to the prior year, primarily due to reduced headcount and professional fees.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued operating losses, substantial accumulated deficit, and the explicit statement of substantial doubt about its ability to continue as a going concern within the next 12 months.

Positives

• Research and development expenses remained stable for the three-month period, indicating continued focus on core operations.
• General and administrative expenses saw a significant reduction of $1.5 million (48%) for the three months ended June 30, 2026, and $2.5 million (44%) for the six months ended June 30, 2026, primarily due to headcount reductions and lower professional fees.
• The company secured $5.1 million in net proceeds from a March 2026 offering and $2.2 million from an At the Market Offering during the six months ended June 30, 2026.
• A new lease agreement was entered into for office and laboratory space, effective October 1, 2026, with a termination of the previous lease without an early termination fee.
• The company's proprietary RedTail platform is advancing, with CLD-401 expected to enter the clinic in Q1 2027.

Negatives

• The company reported a net loss of $4.16 million for the three months and $8.27 million for the six months ended June 30, 2026.
• An accumulated deficit of $149.9 million as of June 30, 2026, highlights significant historical losses.
• There is substantial doubt about the company's ability to continue as a going concern within the next 12 months.
• The company's cash balance of $4.1 million as of June 30, 2026, is insufficient to support operations for at least one year.
• The exercise prices of a substantial portion of outstanding warrants significantly exceed the current market price of the common stock, making their exercise unlikely to provide material liquidity.
• The company may experience dilution if it issues equity securities to raise additional funds.

Risks

• The company has experienced recurring losses from operations and negative cash flows, with expectations of continued net losses.
• The company's ability to continue as a going concern is dependent on its ability to raise additional funding, and there is no assurance that such financing will be secured on favorable terms, or at all.
• Issuing equity securities to raise funds may result in dilution for existing stockholders.
• Changes in economic conditions, including rising interest rates, public health issues, lower consumer confidence, volatile equity capital markets, supply chain disruptions, and geopolitical conflicts, may affect operations.
• The development of product candidates is highly uncertain, with numerous risks and uncertainties associated with preclinical and clinical development, regulatory approval, and commercialization.
• The company may be unable to raise sufficient capital to fund its operations, which could force it to delay, reduce, or eliminate research and development programs or future commercialization efforts.

Future Outlook

The company expects to continue incurring significant operating losses and requires substantial additional funding to support its operations and growth strategy. Future capital needs will depend on R&D costs, clinical trial progress, regulatory approvals, manufacturing, commercialization efforts, and intellectual property maintenance. The company anticipates entering the clinic in Q1 2027 with CLD-401.

Management Comments

• The company is pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease using its proprietary RedTail platform.
• The RedTail platform is designed to shield the virus from immune clearance, allowing it to reach tumor sites, induce tumor lysis, and deliver genetic medicines.
• CLD-401, the first lead from the RedTail platform, is expected to enter the clinic in the first quarter of 2027.
• The company has experienced significant operating losses and has an accumulated deficit, requiring substantial additional funding.
• There is substantial doubt about the company's ability to continue as a going concern within 12 months.
• The company plans to raise additional capital through public or private equity or debt financings.

Industry Context

StockSavvy.ai notes that Calidi Biotherapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on oncolytic virus therapies. The company's RedTail platform aims to address a key challenge in the field: systemic delivery to metastatic sites, which has been a limitation for previous oncolytic virus therapies. The company's progress with CLD-401 and its planned clinic entry are significant milestones, but the substantial doubt about its going concern status highlights the inherent risks and funding challenges common in early-stage biotech development.

Comparison to Industry Standards

• The company's net loss of $8.27 million for the first six months of 2026 and accumulated deficit of $149.9 million are substantial for a company at its stage of development, reflecting the high costs associated with drug development.
• The need for significant additional funding is a common challenge for biotechnology companies, especially those advancing novel platforms like Calidi's RedTail technology.
• The company's focus on oncolytic viruses aligns with a growing area of interest in cancer therapy, but the success of its platform will be benchmarked against other emerging therapies and established treatments.
• The company's R&D expenses of $5.15 million for the first six months of 2026 are in line with industry norms for companies in preclinical and early clinical development stages, though the specific costs can vary widely based on the complexity of the technology and trial design.

Management Changes

Legal Proceedings

• Consolidated legal proceedings involving former Chief Accounting Officer and Interim Chief Financial Officer (Tony Kalajian) and former Controller (Hazel Sanchez) are scheduled for trial on May 14, 2027.
• A lawsuit against a former executive assistant alleging breach of fiduciary duty, fraud, and misappropriation of confidential information is scheduled for trial on May 21, 2027.
• A securities matter filed by Yian Zeng is pending, with a hearing on the Company's Motion for Summary Judgment and Mr. Zeng's Motion for Voluntary Dismissal scheduled for August 24, 2026.

Related Party Transactions

• Director F (Mr. Camaisa) provided a personal Guaranty of Lease for the San Diego Lease, with consideration paid to him and a Guarantee Termination Agreement effective September 30, 2026.
• Officer G received severance pay and COBRA premiums, settled in full by June 30, 2026.
• Officer A received severance pay and related benefits, settled in full by June 30, 2026.
• Company A, related to Director G, provided CRO services, with amounts due settled in full by June 30, 2026.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional equity to raise capital.
• The company's ability to continue as a going concern poses a significant risk to all stakeholders.
• Employees may be impacted by reduced headcount, as indicated by the decrease in general and administrative expenses.
• Creditors and suppliers may face uncertainty regarding timely payments if the company cannot secure adequate funding.

Next Steps

• Advance CLD-401 into the clinic in the first quarter of 2027.
• Continue research and development activities for current and future product candidates.
• Seek regulatory approval for product candidates.
• Continue to raise additional capital through public or private equity or debt financings.
• Manage operating expenses, including further headcount adjustments if necessary.
• Transition to a new office and laboratory space effective October 1, 2026.

Key Dates

Recommendation

The company's continued net losses, substantial accumulated deficit, and explicit statement of substantial doubt about its ability to continue as a going concern within the next 12 months present significant financial risks. While the company is advancing its technology, the immediate financial precariousness and the need for substantial future capital raises, which will likely be dilutive, outweigh the potential future upside in the near term.

Keywords

biotechnology, oncolytic virus, genetic medicine, clinical trials, drug development, regenerative medicine, RedTail platform, going concern